TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14662278

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 7788

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7788
Study: 11127574

Group type: EXPERIMENTAL
Intervention: Healon5
Number of subjects: 48

Group type: COMPARATOR
Intervention: Viscoat
Number of subjects: 48
Study: 9176086

Group type: EXPERIMENTAL
Intervention: 5 mg GTN (0.5 mg/ml)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 10 mg GTN (1 mg/ml)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 19
Study: 8458531

Group type: EXPERIMENTAL
Intervention: gemfibrozil 1200 mg daily for 12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 3724077

Group type: EXPERIMENTAL
Intervention: Calcium carbimide (50 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30832648

Group type: EXPERIMENTAL
Intervention: Resveratrol (Resv) combined with Tac
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tac alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30117334

Group type: EXPERIMENTAL
Intervention: Aflibercept plus FOLFIRI
Number of subjects: 332

Group type: COMPARATOR
Intervention: Placebo plus FOLFIRI
Number of subjects: 332
Study: 26758193

Group type: EXPERIMENTAL
Intervention: Nonrandomized studies
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Open-label randomized trials
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Nonrandomized studies and open-label randomized trials
Number of subjects: 146

Group type: COMPARATOR
Intervention: Blinded trials
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Regression to the mean
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Asymmetrical data handling
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Confounding
Number of subjects: 146
Study: 24741684

Group type: EXPERIMENTAL
Intervention: Concentric (CON) protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eccentric (ECC) protocol
Number of subjects: 0
Study: 22339708

Group type: EXPERIMENTAL
Intervention: Tremella mesenterica (Tm) 2 g
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tremella mesenterica (Tm) with omeprazole 20 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Omeprazole 20 mg, clarithromycin 500 mg, and amoxicillin 1000 mg (standard triple therapy)
Number of subjects: 52
Study: 20556775

Group type: EXPERIMENTAL
Intervention: Inhaled oxygen (at normal pressure)
Number of subjects: 387

Group type: COMPARATOR
Intervention: Air (control group)
Number of subjects: 387
Study: 18052949

Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/day
Number of subjects: 328

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study: 16044078

Group type: EXPERIMENTAL
Intervention: Nicorandil (4‐6 mg/h)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (without Nicorandil)
Number of subjects: 40
Study: 12182991

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg q.i.d. for 7 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 10402681

Group type: EXPERIMENTAL
Intervention: Rational thinking style
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experiential thinking style
Number of subjects: 0
Study: 8582435

Group type: EXPERIMENTAL
Intervention: etofibrate 500 mg/day for 5 days
Number of subjects: 6

Group type: COMPARATOR
Intervention: bezafibrate 400 mg/day for 5 days
Number of subjects: 6
Study: 2153424

Group type: EXPERIMENTAL
Intervention: R68070 (400 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Aspirin (400 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (400 mg)
Number of subjects: 9
Study: 7029741

Group type: EXPERIMENTAL
Intervention: Combination of amoxycillin and flucloxacillin (Suprapen; Bencard)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Antibiotics only if postoperative sepsis developed (Control)
Number of subjects: 46
Study: 30771559

Group type: EXPERIMENTAL
Intervention: Hydrate Philly intervention (multi-level intervention including hydration stations, water safety testing, reusable water bottles, and promotion of tap water)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Hydrate Philly intervention
Number of subjects: 28
Study: 28698331

Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART) using high-viscosity glass ionomer cement
Number of subjects: 240

Group type: COMPARATOR
Intervention: Composite resin restoration
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART)
Number of subjects: 240
Study: 26488865

Group type: EXPERIMENTAL
Intervention: Video-Assisted Thyroidectomy (VAT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional Thyroidectomy (CT)
Number of subjects: 33
Study: 25189746

Group type: EXPERIMENTAL
Intervention: Experimental conditions with varying weights (3 boxes × 14 weights for males, 3 boxes × 9 weights for females)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Experimental conditions with varying weights
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Participants' linguistic term for perceived weight
Number of subjects: 69
Study: 22641412

Group type: EXPERIMENTAL
Intervention: MALDI-TOF-MS diagnostic model for BD
Number of subjects: 49
Study: 19929591

Group type: EXPERIMENTAL
Intervention: Duloxetine 40 mg twice daily
Number of subjects: 2760

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2760
Study: 17498126

Group type: EXPERIMENTAL
Intervention: Benazepril (2.5-5 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 16177001

Group type: EXPERIMENTAL
Intervention: Pilocarpine (5 mg oral solution)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12079902

Group type: EXPERIMENTAL
Intervention: Standardised protocol for measurement of shoulder movements using a gravity inclinometer
Number of subjects: 6
Study: 9651408

Group type: EXPERIMENTAL
Intervention: Information from a health professional about the importance of a primary care provider and assistance with making an appointment, continued for up to 3 months after the index ED visit.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Information from a clerical employee about the importance of a primary care provider and assistance with making an appointment, continued for up to 3 months after the index ED visit.
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (comparison group).
Number of subjects: 0
Study: 7608283

Group type: EXPERIMENTAL
Intervention: Beta-blocker bisoprolol (4.25 +/- 1.2 mg/day) for 4 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Levothyroxine (L-T4) therapy
Number of subjects: 25
Study: 2172309

Group type: EXPERIMENTAL
Intervention: Diet-laxative (DL) group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (C) group
Number of subjects: 100
Study: 6820492

Group type: EXPERIMENTAL
Intervention: 1 dose of 1500 mg sodium valproate
Number of subjects: 6

Group type: COMPARATOR
Intervention: 3 doses of 1500 mg sodium valproate
Number of subjects: 6
Study: 30406290

Group type: EXPERIMENTAL
Intervention: Multi-contour delineation based on a majority vote algorithm (MCD)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Consensus-based delineation (CBD)
Number of subjects: 16
Study: 29087863

Group type: EXPERIMENTAL
Intervention: AMT + RELAX
Number of subjects: 58

Group type: COMPARATOR
Intervention: AMT
Number of subjects: 58
Study: 26721141

Group type: EXPERIMENTAL
Intervention: Relaxing needling manipulation combined with exercise therapy (Group A)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Exercise therapy (Group B)
Number of subjects: 64
Study: 23795874

Group type: EXPERIMENTAL
Intervention: Buprenorphine treatment
Number of subjects: 87

Group type: COMPARATOR
Intervention: Buprenorphine treatment (cocaine users)
Number of subjects: 87
Study: 20092916

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Palpation
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Johnson's technique
Number of subjects: 174

Group type: COMPARATOR
Intervention: Palpation and Johnson's technique
Number of subjects: 174
Study: 19157776

Group type: EXPERIMENTAL
Intervention: Quetiapine (25mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 19124099

Group type: EXPERIMENTAL
Intervention: 300 mg iodine/ml (Iopromide 300)
Number of subjects: 71

Group type: COMPARATOR
Intervention: 400 mg iodine/ml (Iomeprol 400)
Number of subjects: 71
Study: 15804728

Group type: EXPERIMENTAL
Intervention: Low-dose hormone therapy (HT)
Number of subjects: 0
Study: 12470755

Group type: EXPERIMENTAL
Intervention: latanoprost 0.005% once daily
Number of subjects: 165

Group type: COMPARATOR
Intervention: unoprostone 0.15% twice daily
Number of subjects: 165
Study: 9388037

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 7526098

Group type: EXPERIMENTAL
Intervention: STH (streptomycin, thiacetazone, and isoniazid for two months followed by thiacetazone and isoniazid for ten months)
Number of subjects: 191

Group type: COMPARATOR
Intervention: RHZ (isoniazid, rifampicin, and pyrazinamide for two months followed by isoniazid and rifampicin for seven months)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: STH
Number of subjects: 191

Group type: COMPARATOR
Intervention: RHZ
Number of subjects: 191
Study: 2889957

Group type: EXPERIMENTAL
Intervention: APD (aminohydroxy-propylidene-bisphosphonate), 300 mg daily (n = 70)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (n = 61)
Number of subjects: 131
Study: 12207762

Group type: EXPERIMENTAL
Intervention: Dead Sea climatotherapy/pseudocatalase cream (PC-KUS)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Dead Sea climatotherapy alone
Number of subjects: 59

Group type: COMPARATOR
Intervention: Dead Sea climatotherapy/placebo cream
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional pseudocatalase monotherapy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Narrowband UVB activated pseudocatalase cream (PC-KUS)
Number of subjects: 59
Study: 29659120

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for SAD (CBT-SAD)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Light therapy (LT)
Number of subjects: 177
Study: 27033936

Group type: EXPERIMENTAL
Intervention: Nitric oxide releasing solution (NORS)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Tilmicosin (macrolide antibiotic)
Number of subjects: 840
Study: 25193008

Group type: EXPERIMENTAL
Intervention: Lapis judaicus (2g per day for 10 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lapis judaicus
Number of subjects: 60
Study: 22114906

Group type: EXPERIMENTAL
Intervention: Olmesartan/hydrochlorothiazide 40/25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olmesartan 40 mg
Number of subjects: 0
Study: 20300753

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (methylprednisolone)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Eritrosedimention rate (ESR)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Visual analogical scale score (VAS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ESR at baseline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: VAS difference from first to second month
Number of subjects: 20
Study: 18608825

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 16006882

Group type: EXPERIMENTAL
Intervention: Lidocaine periprostatic nerve block (PPNB)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Diclofenac suppository (DS)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Combination of lidocaine PPNB and DS
Number of subjects: 165
Study: 12479658

Group type: COMPARATOR
Intervention: Mood stabilizer alone
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Adjunctive antidepressant
Number of subjects: 39
Study: 10342350

Group type: EXPERIMENTAL
Intervention: Active ultrasound treatment (20 minutes daily for 75 days)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo treatment (20 minutes daily for 75 days)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Active ultrasound treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 32
Study: 7718317

Group type: EXPERIMENTAL
Intervention: Weekly 20 mg mitoxantrone intravesically for 6 weeks after TUR
Number of subjects: 126

Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 126
Study: 1940194

Group type: EXPERIMENTAL
Intervention: Ornoprostil
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7185773

Group type: EXPERIMENTAL
Intervention: Prazepam (tranquillizing agent)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24
Study: 31039579

Group type: EXPERIMENTAL
Intervention: Prefrontal tDCS (transcranial direct current stimulation) administered to the left prefrontal cortex prior to CBT for eight weekly sessions
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Prefrontal tDCS in individuals with high left prefrontal cortex activation at baseline
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 39
Study: 29030644

Group type: EXPERIMENTAL
Intervention: Jump training program
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (bed rest without intervention)
Number of subjects: 23
Study: 27424295

Group type: EXPERIMENTAL
Intervention: Suvorexant 15 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Suvorexant 30 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Zopiclone 7.5 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 23829494

Group type: EXPERIMENTAL
Intervention: Racemic salbutamol (200 μg q.i.d.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Levosalbutamol (100 μg q.i.d.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22488800

Group type: EXPERIMENTAL
Intervention: Intensive pelvic floor muscle exercises (PG‐PFME)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard pelvic floor muscle exercises (F‐PFME)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Radical retropubic prostatectomy (RRP)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Postoperative continence status
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Non-nerve sparing approach
Number of subjects: 66
Study: 19003983

Group type: EXPERIMENTAL
Intervention: TOP2A positivity in chemoresistant patients
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Etoposide (single agent)
Number of subjects: 148
Study: 17213244

Group type: EXPERIMENTAL
Intervention: Biodex Stability System (one-leg stance protocol)
Number of subjects: 70
Study: 15893351

Group type: EXPERIMENTAL
Intervention: Killed whole‐cell Leishmania amazonensis vaccine (3 doses at 20-day intervals)
Number of subjects: 2597

Group type: COMPARATOR
Intervention: Placebo (3 doses at 20-day intervals)
Number of subjects: 2597
Study: 11474721

Group type: EXPERIMENTAL
Intervention: Response time restriction
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Personality inventories
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Response time limitation
Number of subjects: 540
Study: 9758071

Group type: EXPERIMENTAL
Intervention: Lidocaine/bupivicaine local anesthetic (LA)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline (S)
Number of subjects: 7
Study: 7511324

Group type: EXPERIMENTAL
Intervention: Dextran-coated superparamagnetic iron oxide particles (BMS 180549) at a dose of 1.7 mg Fe/kg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dextran-coated superparamagnetic iron oxide particles (BMS 180549) at doses ranging from 0.3 to 1.7 mg Fe/kg
Number of subjects: 5
Study: 3293671

Group type: EXPERIMENTAL
Intervention: Short-term emotional support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Information-provision
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 0
Study: 30449151

Group type: EXPERIMENTAL
Intervention: Verum external trigeminal nerve stimulation (CEFALY Technology) for 1 hour
Number of subjects: 106

Group type: COMPARATOR
Intervention: Sham external trigeminal nerve stimulation
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Verum external trigeminal nerve stimulation for migraine without aura
Number of subjects: 106

Group type: COMPARATOR
Intervention: Sham external trigeminal nerve stimulation for migraine without aura
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Verum external trigeminal nerve stimulation for migraine with aura
Number of subjects: 106

Group type: COMPARATOR
Intervention: Sham external trigeminal nerve stimulation for migraine with aura
Number of subjects: 106
Study: 28158524

Group type: EXPERIMENTAL
Intervention: Participatory trial intervention (details on dosage and duration not available)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized wait-list control group design
Number of subjects: 0
Study: 25582785

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of lidocaine and bupivacaine
Number of subjects: 90
Study: 23823050

Group type: EXPERIMENTAL
Intervention: Locking Compression Plate (LCP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Dynamic Compression Plate (DCP)
Number of subjects: 42
Study: 22132379

Group type: EXPERIMENTAL
Intervention: Small‐sided games-based exercise (45 minutes, three times per week for four weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (one-month gym membership after the trial)
Number of subjects: 20
Study: 20183690

Group type: EXPERIMENTAL
Intervention: Guided Internet-delivered self-help treatment (5 weekly text modules, video exposure, Internet support)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Live-exposure treatment (1 session of 3 hours following a brief orientation)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Spider phobia questionnaire
Number of subjects: 30
Study: 17078096

Group type: EXPERIMENTAL
Intervention: p16(INK4a)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: HC2
Number of subjects: 400
Study: 16929589

Group type: EXPERIMENTAL
Intervention: Combination therapy of interferon alfa-2b plus ribavirin for 48 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination therapy of interferon alfa-2b plus ribavirin
Number of subjects: 100
Study: 11087644

Group type: EXPERIMENTAL
Intervention: Pre-operative radiotherapy (20 Gy/5 days) and intraoperative radiotherapy (20 Gy using 8-12 electrons)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Combined treatment (pre-operative and intraoperative radiotherapy)
Number of subjects: 78
Study: 8967308

Group type: EXPERIMENTAL
Intervention: Non-fractioned heparin (Liquemine)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Low molecular weight heparin (Fraxiparine)
Number of subjects: 500
Study: 14621767

Group type: EXPERIMENTAL
Intervention: Orthotopic liver transplantation (OLT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Heterotopic liver transplantation (HLT)
Number of subjects: 28
Study: 4083303

Group type: EXPERIMENTAL
Intervention: Evening dosing with Uniphyl (10 P.M.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morning dosing with Uniphyl (8 A.M.)
Number of subjects: 0
Study: 30282639

Group type: EXPERIMENTAL
Intervention: Comprehensive CR (exercise + education)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Exercise-only CR
Number of subjects: 115

Group type: COMPARATOR
Intervention: Comprehensive CR
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control (wait-list)
Number of subjects: 115
Study: 28192220

Group type: EXPERIMENTAL
Intervention: Feedback Condition (FC) - participants received vibrotactile feedback from their fork when eating too fast (more than one bite per 10 s)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Non‐Feedback Condition (NFC)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Feedback Condition (FC)
Number of subjects: 114
Study: 24661917

Group type: EXPERIMENTAL
Intervention: Differential-time-to-positivity (DTP) method without catheter withdrawal
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard strategy requiring catheter withdrawal
Number of subjects: 52
Study: 23534865

Group type: EXPERIMENTAL
Intervention: Folate-fortified oral contraceptive (OC)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Marketed oral contraceptive (OC)
Number of subjects: 385
Study: 22640829

Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg days 1 and 15; paclitaxel 90 mg/m(2) days 1, 8, and 15, every 4 weeks (Arm A)
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg day 1; capecitabine 1000 mg/m(2) b.i.d., days 1‐14, every 3 weeks (Arm B)
Number of subjects: 561

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 561
Study: 19098116

Group type: EXPERIMENTAL
Intervention: Soccer group (SO)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Running group (RU)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 36
Study: 17562950

Group type: EXPERIMENTAL
Intervention: Women with heart failure
Number of subjects: 7599

Group type: COMPARATOR
Intervention: Men with heart failure
Number of subjects: 7599
Study: 15272398

Group type: EXPERIMENTAL
Intervention: 23-valent polysaccharide vaccine
Number of subjects: 0
Study: 12202123

Group type: COMPARATOR
Intervention: Serum COMP levels measured at baseline and study end
Number of subjects: 48
Study: 10353371

Group type: COMPARATOR
Intervention: Perceptual fluency as a cue for recognition in amnesic patients (Experiment 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perceptual fluency as a cue for recognition in amnesic patients (Experiment 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perceptual fluency effect on judgments for studied and unstudied items (Experiment 2)
Number of subjects: 0
Study: 8942331

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29